Skip to main content
Formycon AG logo

Formycon AG — Investor Relations & Filings

Ticker · FYB ISIN · DE000A1EWVY8 LEI · 39120005TZ76GQOY8Z19 F Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2026-03-18 Report Publication Anno…
Country DE Germany
Listing F FYB

About Formycon AG

https://www.formycon.com/en/

Formycon AG is an independent, globally operating biopharmaceutical company specializing in the development of high-quality biosimilars. As a pure-play biosimilar developer, the company focuses on creating follow-on products for complex biopharmaceutical medicines after their patent protection has expired. The core mission is to enhance patient access to safe, effective, and affordable biologic therapies. Formycon's development activities are concentrated in therapeutic areas with high medical need, including ophthalmology and immunology. The company manages the entire development process, from analytics and process development to clinical trials and regulatory approval submissions for its biosimilar candidates.

Recent filings

Filing Released Lang Actions
Formycon AG postpones the publication of its audited annual and consolidated financial statements for 2025
Report Publication Announcement Classification · 95% confidence The document is an official announcement from Formycon AG regarding the postponement of the publication of its audited annual financial statements. It is not the report itself, but rather a regulatory disclosure (Ad-hoc announcement) informing the market about a change in the reporting schedule. According to the 'Menu vs Meal' rule, since this is an announcement regarding the timing of a report rather than the report itself, it falls under the category of Report Publication Announcement (RPA).
2026-03-18 English
Formycon AG publishes preliminary figures for the 2025 fiscal year
Earnings Release Classification · 100% confidence The document is an 'Ad-hoc' announcement regarding preliminary financial figures for the 2025 fiscal year. It provides key highlights of revenue and EBITDA performance ahead of the full annual report publication. According to the filing definitions, an initial announcement of quarterly or periodical financial results (key highlights only) is classified as an Earnings Release (ER). The document explicitly states that the final annual report will be published later, confirming this is an earnings release and not the annual report itself. FY 2025
2026-03-04 English
Formycon announces positive clinical data for Keytruda biosimilar candidate FYB206 (pembrolizumab)
Regulatory Filings Classification · 95% confidence The document is a corporate press release issued by Formycon AG announcing positive clinical trial results for a biosimilar candidate (FYB206). It follows the standard format of a corporate news announcement disseminated via a regulatory news service (EQS Group). It does not constitute a formal financial report, proxy statement, or regulatory filing required by law, but rather a public relations announcement regarding operational progress. Therefore, it is classified as a general regulatory announcement/corporate news.
2026-02-25 English
Lotus Pharmaceutical becomes commercialization partner for Formycon's Keytruda biosimilar candidate FYB206 across major parts of the Asia-Pacific Region
Regulatory Filings Classification · 95% confidence The document is a press release announcing a new commercialization partnership between Formycon AG and Lotus Pharmaceutical regarding a biosimilar candidate. It follows the standard format of a corporate news announcement, including quotes from executives, background information on the companies, and a disclaimer. It does not constitute a formal financial report, proxy statement, or regulatory filing, but rather a corporate news release disseminated via the EQS News service.
2026-02-11 English
Formycon AG: Active Ownership Fund SICAV SIF SCS, sell
Director's Dealing Classification · 100% confidence The document is a formal notification of a transaction by a person discharging managerial responsibilities (PDMR) or a person closely associated with them. It explicitly identifies the person (Active Ownership Fund SICAV SIF SCS, associated with Klaus Röhrig, a member of the supervisory body) and details the disposal of a financial instrument. This aligns perfectly with the definition of a Director's Dealing (DIRS) filing.
2026-01-14 English
Formycon AG: Active Ownership Fund SICAV SIF SCS, sell
Director's Dealing Classification · 100% confidence The document is a formal notification of a transaction by a person discharging managerial responsibilities (PDMR) or a person closely associated with them. It explicitly identifies the transaction as 'Directors’ Dealings' and provides details on the person involved (Active Ownership Fund SICAV SIF SCS, associated with Klaus Röhrig), the issuer (Formycon AG), the nature of the transaction (disposal), and the financial instrument details. This aligns perfectly with the definition for Director's Dealing (DIRS).
2026-01-13 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.